CureVac (NASDAQ:CVAC - Get Free Report)'s stock price rose 9.9% during trading on Monday . The stock traded as high as $3.01 and last traded at $3.01. Approximately 307,717 shares were traded during trading, a decline of 68% from the average daily volume of 953,040 shares. The stock had previously closed at $2.74.
Analysts Set New Price Targets
Separately, JMP Securities dropped their price objective on CureVac from $18.00 to $16.00 and set a "market outperform" rating on the stock in a report on Friday, August 16th.
Get Our Latest Report on CVAC
CureVac Stock Performance
The company has a market cap of $653.73 million, a P/E ratio of -2.20, a PEG ratio of 1.94 and a beta of 2.62. The company has a 50 day moving average price of $3.33 and a 200-day moving average price of $3.29. The company has a quick ratio of 2.28, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.
CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). CureVac had a negative return on equity of 57.18% and a negative net margin of 422.66%. The business had revenue of $15.55 million during the quarter, compared to the consensus estimate of $10.07 million. Equities analysts expect that CureVac will post 0.05 EPS for the current fiscal year.
Institutional Trading of CureVac
Several institutional investors have recently modified their holdings of the company. Jump Financial LLC purchased a new stake in shares of CureVac during the fourth quarter valued at $346,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of CureVac by 45.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 44,122 shares of the company's stock valued at $184,000 after purchasing an additional 13,687 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of CureVac during the fourth quarter valued at $68,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of CureVac during the fourth quarter valued at $160,000. Finally, Aristides Capital LLC purchased a new stake in shares of CureVac during the fourth quarter valued at $100,000. Institutional investors and hedge funds own 17.26% of the company's stock.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Articles
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
